netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group

Preferred Prescribing list for South Staffordshire CCGs, including Burton Hospital NHS Foundation Trust and
Cannock and Stafford Hospitals Foundation Trust

Useful Links

BNFSPC  Area Prescribing Group Minutes CCG Patient Group Directions and Patient Specific Directions Prescribing Commissioning and over the counter
Feedback To Us Link
BNF For Children New Medicines Committee Documents CCG Newsletters NHS England Patient Group Directions    High Cost Drugs
MHRA Drug Safety Updates Decline To Prescribe Form Vaccine Update Prescribing Audits  Communications and drug discontinuations
Care Home Prescribing Resourses Cross Border prescribing guideline     


Interim Clinical Information 

RICaDs and ESCAs
Burton Hospital NHS Trust
Essential Shared Care Agreements
RICaDs MPFT Mental Health Essential Shared Care Agreements
Clinical Formularies and Guidelines
Area Prescribing Group Guidelines Woundcare Formulary Antimicrobial Guidance Continence Prescribing Formulary
CCG Formularies
North Staffs Joint Formulary Birmingham and Surrounds Formulary Derbyshire Formulary  Wolverhampton Formulary


News Feed

4/8/20 Updated Gluten-Free Prescribing policy 2020

The updated Gluten-Free Prescribing policy 2020 can be found on the Homepage, Area Prescribing Group Guidelines link, BNF Chapter 9 Nutrition and Blood – Gluten Free prescribing on the South Staffordshire Joint Formulary.

24/7/2020 - Updated Rheumatology ESCA’s

Midlands Partnership NHS Foundation Trust (MPFT) have updated their contact details for their Rheumatology ESCA’s to reflect their dedicated email

The updated documents can be found on the ESCA’s link on the North Staffordshire Joint Formulary Home page.

07/05/2020 - New Covid-19 information link

The South Staffordshire Joint Formulary has a new COVID 19 link titled Interim Clinical Information. Please use this link to access local and national documents recommending advice and guidance during this time. If you have any queries relating to this please use the Feedback tab on the formulary front page.

Medicines Information Team

19/03/20 Esmya: Urgent patient level recall

Gedeon Richter (UK) Ltd is recalling all unexpired stock of Ulipristal acetate (Esmya) from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine. To protect patients while a safety review is conducted, the European Medicines Agency's safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.

Clinicians must contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should be provided advice about other possible treatments for uterine fibroids.  

24/02/20: Three Insuman preparations to be discontinued.

Three presentations of Insuman Basal and Insuman Comb are to be discontinued owing to limited capacity at the manufacturing site. The manufacturer says the discontinuations are not due to any safety issue.

The presentations being discontinued are:

  • Insuman Comb 15 100IU/mL suspension for injection in a cartridge (expected end of supply June 2020). This is the only presentation of Insuman Comb 15.
  • Insuman Basal 100IU/mL suspension for injection in a vial (expected end of supply May 2020).
  • Insuman Comb 25 100IU/mL suspension for injection in a vial (expected end of supply June 2020).

No new patients should be started on these presentations, and existing patients should be switched to a suitable alternative. See individual entries on the formulary for alternatives.

21/11/19: Asthma guidelines for Staffordshire and SOT CCGs

The APC/APG has approved the Staffordshire and SOT CCGs Asthma Guidelines. This document is now available on netFormulary. Clinicians should familiarise themselves with the document and employ its use in clinical practice. Any queries can be directed to the Medicines Optimisation Team. 

>>> more news


  1. The Preferred Prescribing List for the various therapeutic sections of  the British National Formulary (BNF) can be accessed via the links

   2.     PDF How to use guide

   3.   Drugs are colour coded according to the following criteria:


Status Description
Red Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  
Amber Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  
Amber E Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)
Green Suitable first-line drugs for implementation in Primary Care  
Green Formulary South Staffs Formulary Choice


   Visits = 380122
   Last updated: 29/09/2020 08:00:28..